Clinical Trials Browser

Phase 1 × adavosertib × Clear all

Advanced Solid Tumours

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Muscle Invasive Bladder Cancer

Neoplasm Metastasis

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Brain Neoplasms, Meningeal Carcinomatosis

Glioblastoma

Squamous Cell Carcinoma of Head and Neck, Laryngeal Neoplasms

Uterine Cervical Neoplasms, Vaginal Neoplasms, Carcinoma, Endometrioid

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Gliosarcoma

Solid Tumors

Esophageal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Ovarian Neoplasms

Advanced Solid Tumours

Advanced Solid Tumors

Advanced Solid Tumours

Advanced Solid Tumours

Solid Tumors

Squamous Cell Carcinoma of Head and Neck

Colorectal Neoplasms

Small Cell Lung Carcinoma

Advanced Solid Tumours

Squamous Cell Carcinoma of Head and Neck

Leukemia, Myeloid, Acute

Clinical Trials

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

BISCAY

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

WISTERIA

Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

MK-1775-001

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib

ADME

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

AZD1775 for Advanced Solid Tumors

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia